^
    4d
    Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov)
    P1/2, N=11, Terminated, University of Michigan Rogel Cancer Center | Active, not recruiting --> Terminated; Lack of accrual
    Trial termination
    |
    Ninlaro (ixazomib) • Istodax (romidepsin)
    10d
    PTCL13: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=89, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Completed --> Active, not recruiting
    Enrollment closed
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Istodax (romidepsin)
    16d
    Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas (clinicaltrials.gov)
    P1, N=114, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    bortezomib • Copiktra (duvelisib) • Istodax (romidepsin)
    17d
    Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
    P3, N=86, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    gemcitabine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)
    1m
    PTCL13: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=89, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed
    Trial completion
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Istodax (romidepsin)
    1m
    Targeting histone deacetylation, cell cycle regulators and heat shock proteins as novel therapeutic strategies for penile cancers. (PubMed, NPJ Precis Oncol)
    A paclitaxel, ifosfamide, and cisplatin-based regimen achieves response rates around 65%...Compared to standard chemotherapy (e.g. cisplatin, 5-FU, ifosfamide, irinotecan), treatment with romidepsin, quisinostat (HDAC inhibitors (i)), palbociclib (CDK4/6i), or 17-AAG and PU-H71 (HSP90i) reduced cell viability, induced apoptosis, and led to G2 / M cell cycle arrest in most PeCa cells. This research underscores the therapeutic potential of using HDAC, CDK4/6, and HSP90 inhibitors for PeCa management and reveals additional promising targets and biomarkers for future strategies.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    cisplatin • Ibrance (palbociclib) • paclitaxel • 5-fluorouracil • ifosfamide • irinotecan • Istodax (romidepsin) • quisinostat (JNJ 26481585) • zelavespib intravenous (PU-H71 IV)
    2ms
    Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents (clinicaltrials.gov)
    P1, N=12, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended
    Trial suspension
    |
    Imfinzi (durvalumab) • Istodax (romidepsin)
    3ms
    Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    TNFRSF8 positive
    |
    lenalidomide • dexamethasone • Istodax (romidepsin) • Onureg (azacitidine oral)
    4ms
    SYNACTHIV: Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (clinicaltrials.gov)
    P1, N=9, Completed, ANRS, Emerging Infectious Diseases | Recruiting --> Completed | N=15 --> 9 | Trial completion date: Apr 2026 --> Dec 2025 | Trial primary completion date: Apr 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    decitabine • Istodax (romidepsin)
    4ms
    EPI-SauriCas9-based mouse ovarian cancer models recapitulating pten deletion in patients. (PubMed, Commun Biol)
    High-throughput drug screening identifies FK228 and thioguanine as promising therapeutic candidates, both of which show in vivo efficacy and are validated in PTEN-deleted organoids. Together, these results establish MEPP as a platform for studying PTEN-deleted ovarian cancer and provide a strategy for generating clinically relevant tumor models through targeted gene editing.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
    |
    TP53 mutation • PTEN deletion • TP53 deletion
    |
    Istodax (romidepsin) • thioguanine
    4ms
    In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma. (PubMed, Cancers (Basel))
    In vitro we identified that romidepsin synergizes with doxorubicin and etoposide and that it increases the efficacy of the standard of care combinations VDC/IE. In vivo, the combination of romidepsin and ifosfamide/etoposide (IE) leads to a significant decrease in tumor volume compared to that of IE alone. Our data indicates that romidepsin improves efficacy of chemotherapeutic agents in vitro and leads to a decreased tumor volume in vivo, suggesting that the addition of romidepsin may improve upfront treatment in ES patients.
    Preclinical • Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7)
    |
    doxorubicin hydrochloride • ifosfamide • etoposide IV • Istodax (romidepsin)
    7ms
    Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. (PubMed, Drug Resist Updat)
    In this work, we discovered that the combination of class I histone deacetylase (HDAC) inhibitors, such as romidepsin, with a novel RNA helicase eIF4A inhibitor, des-methyl pateamine A (DMPatA), induces robust and persistent hyperacetylation, significantly exceeding the levels and duration observed with HDAC inhibitor monotherapy...The combination does not appear to induce known resistance mechanisms such as drug efflux; elevated MYC expression, rather than inducing resistance, sensitizes PDAC cells to treatment. These studies support translation of this synergistic combination to the clinic.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    Istodax (romidepsin)